Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease

Neurologia i Neurochirurgia Polska

Volumn 43, Issue 3, 2009, Pages 272-285

  Białecka, Monika ^a   Rabowski, Piotr ^b,c   Honczarenko, Krystyna ^a   Roszmann, Anna ^b,c   Sławek, Jarosław ^b,c  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b ST ADALBERT HOSPITAL   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Genetic polymorphism; Homocysteine; Parkinson's disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BETAINE HOMOCYSTEINE METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE; COBALAMIN; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; PYRIDOXINE; VITAMIN;

ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ATHEROSCLEROSIS; CLINICAL TRIAL; COMORBIDITY; DEMENTIA; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; HYPERHOMOCYSTEINEMIA; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; REVIEW; RISK FACTOR; SIDE EFFECT; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; COMORBIDITY; CYSTATHIONINE BETA-SYNTHASE; DOPAMINE AGENTS; ENVIRONMENTAL EXPOSURE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PARKINSON DISEASE; RISK FACTORS; VASCULAR DISEASES; VITAMIN B 12; VITAMIN B COMPLEX;

EID: 68149149009     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Bots M.L., Launer L.J., Lindemans J., et al. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Intern Med 1997; 242: 339-347.
2. Bostom A.G., Rosenberg I.H., Silbershatz H., et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999; 131: 352-355.
3. Seshadri A., Beiser A., Selhub J., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483.
4. den Heijer T., Vermeer S.E., Clarke R., et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003; 126: 170-175.
5. Zoccolella S., Martino D., Defazio G., et al. Hyperhomocysteinemia in movement disorders: current evidence and hypotheses. Curr Vasc Pharmacol 2006; 4: 237-243.
6. Isobe C., Murata T., Sato C., et al. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci 2005; 77: 1836-1843.
7. O'Suilleabhain P.E., Sung V., Hernandez C., et al. Elevated plasma homocysteine level in patients with Parkinson's disease. Arch Neurol 2004; 61: 865-868.
8. Zoccolella S., Lamberti P., Iliceto G., et al. Plasma homocysteine levels in L-dopa treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005; 43: 1107-1110.
9. Sato Y., Iwamoto J., Kanoko T., et al. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005; 118: 1250-1255.
10. Kuhn W., Roebroek R., Blom H., et al. Hyperhomocysteinemia in Parkinson's disease. J Neurol 1998; 245: 811-812.
11. Muller T., Werne B., Fowler B., et al. Nigral endothelial dysfunction, homocysteine and Parkinson's disease. Lancet 1999; 354: 126-127.
12. Yasui K., Kowa H., Nakaso K., et al. Plasma homocyssteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000; 55: 437-440.
13. Blandini F., Fancellu R., Martignoni E., et al. Plasma homocysteine and l-dopa metabolism in paatients with Parkinson's disease. Clin Chem 2001; 47: 1102-1104.
14. Nakaso K., Yasui K., Kowa H., et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-dopa, homocysteine, and MTHFR genotype. J Neurol Sci 2003; 207: 19-23.
15. Immamura K., Takeshima T., Nakaso K., et al. Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. Neuroreport 2007; 18: 1319-1322.
16. O'Suilleabhain P.E., Oberle R., Bartis C., et al. Clinical course in Parkinson's disease with elevated homocysteine. Parkinsonism Relat Disord 2006; 12: 103-107.
17. Duan W., Ladenheim B., Cutler R.G., et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002; 80: 101-110.
18. Reuters S., Sachdev P. Homocysteine in neuropsychiatric disorders of the elderly. Int J Geriatr Psychiatry 2002; 17: 859-864.
19. Siniscalchi A., Mancuso F., Gallelli L., et al. Increase in plasma homocysteine levels induced by drug treatments in neurologic patients. Pharmacol Res 2005; 52: 367-375.
20. Zhu B.Y. Cathechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Met 2002; 63: 886-891.
21. Postuma R.B., Lang A.E. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004; 63: 886-891.
22. Lawrence de Koning A.B., Werstuck G.H., Zhou J., et al. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003; 36: 431-441.
23. Blundell G., Jones B.G., Rose F.A., et al. Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996; 122: 163-172.
24. Suhara T., Fukuo K., Yasuda O., et al. Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways. Hypertension 2004; 43: 1208-1213.
25. Mangiagalli A., Samuele A., Armentero M.T., et al. Effects of homocysteine on apoptosis-related proteins and anti-oxidant system in isolated human lymphocytes. Eur J Biochem 2004; 271: 1671-1676.
26. Agnati L.F., Ferre S., Genedani S., et al. Allosteric modulation of dopamine D2 receptors by homocysteine. J Proteome Res 2006; 5: 3077-3083.
27. Zoccolella S., Lamberti P., Iliceto G., et al. Elevated plasma homocysteine levels in L-dopa -treated Parkinson's disease with dyskinesias. Clin Chem Lab Med 2006; 44: 863-866.
28. Ueland P.M., Hustad S., Schneede J., et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22: 195-201.
29. D'Angelo A., Mazzola G., Fermo I. Gene-gene and gene-environmental interactions in mild hyperhomocysteinemia. Pathophysiol Haemost Thromb 2003; 33: 337-341.
30. Mattson M., Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003; 26: 137-146.
31. Kluijtmans L.A., Young I. S., Boreham C.A., et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 2003; 101: 2483-2488.
32. Yasui K., Kowa H., Nakaso K., et al. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000; 55: 437-440.
33. Religa D., Czyzewski K., Styczynska M., et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett 2006; 404: 56-60.
34. Todorovic Z., Dzoljic E., Novakovic I., et al. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 2006; 248: 56-61.
35. Fodinger M., Buchmayer H., Heinz G., et al. Effect of MTHFR 1298A→C and MTHFR 677C→T genotypes on total homocysteine, folate, and vitamin B(12) plasma concentrations in kidney graft recipients. J Am Soc Nephrol 2000; 11: 1918-1925.
36. van der Put N.M., Steegers-Theunissen R.P., Frosst P., et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-1071.
37. van der Put N.M., Gabreels F., Stevens E.M., et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044-1051.
38. Siniscalchi A., Gallelli L., Mercuri N.B., et al. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa. Nutr Neurosci 2006; 9: 11-16.
39. Liu X.X., Wilson K., Charlton C.G. Effects of L-dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa. Life Sci 2000; 66: 2277-2288.
40. Lamberti P., Zoccolella S., Armenise E., et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005; 12: 365-368.
41. Muller T., Renger K., Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004; 61: 657-660.
42. Yasui K., Nakaso K., Kowa H., et al. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003; 108: 66-67.
43. Gaustadnes M., Wilcken B., Oliveriusova J., et al. The molecular basis of cystathionine beta-synthase deficiency in Australian patients: genotype-phenotype correlations and response to treatment. Hum Mutat 2002; 20: 117-126.
44. Meyer K., Fredriksen A., Ueland P.M. High-level multiplex genotyping of polymorphisms involved in folate or homocysteine metabolism by matrix-assisted laser desorption/ionization mass spectrometry. Clin Chem 2004; 50: 391-402.
45. de Franchis R., Fermo I., Mazzola G., et al. Contribution of the cystathionine beta-synthase gene (844ins68) polymorphism to the risk of early-onset venous and arterial occlusive diseaseand of fasting hyperhomocysteinemia. Thromb Haemost 2000; 84: 576-582.
46. Tsai M.Y., Bignell M., Schwichtenberg K., et al. High prevalence of a mutation in the cystathionine beta-synthase gene. Am J Hum Genet 1996; 59: 1262-1267.
47. Sperandeo M.P., de Franchis R., Andria G., et al. A 68-bp insertion found in a homocystinuric patient is a common variant and is skipped by alternative splicing of the cystathionine beta-synthase mRNA. Am J Hum Genet 1996; 59: 1391-1393.
48. Aras O., Hanson N.Q., Yang F., et al. Influence of 699CT and 1080CT polymorphism of the cysthationine beta-synthase gene on plasma homocysteine levels. Clin Genet 2000; 58: 455-459.
49. Kluijtmans L.A., Boers G.H., Trijbels F.J., et al. A common 844INS68 insertion variant in the cystathionine beta-synthase gene. Biochem Mol Med 1997; 62: 23-25.
50. Gaustadnes M., Rudiger N., Rasmussen K., et al. Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants. Thromb Haemost 2000; 83: 554-558.
51. Morita H., Kurihara H., Sugiyama T., et al. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol 1999; 19: 298-302.
52. Gaughan D.J., Kluijtmans L.A., Barbaux S., et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001; 157: 451-456.
53. Gueant-Rodriguez R.M., Juilliere Y., Candito M., et al. Association of MTRR A66G polymorphism (but not of MTHFR C677T and A1298C, MTRA2756G, TCN C776G) with homocysteine and coronary artery disease in the French population. Thromb Haemost 2005; 94: 510-515.
54. Leclerc D., Odievre M., Wu Q., et al. Molecular cloning, expression and physical mapping of the human methionine synthase reductase gene. Gene 1999; 240: 75-88.
55. Ma J., Stampfer M.J., Christensen B., et al. A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst (e) ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8: 825-829.
56. Watkins D., Rosenblatt D.S. Functional methionine synthase deficiency (cblE and cblG): clinical and biochemical heterogeneity. Am J Med Genet 1989; 34: 427-434.
57. Harmon D.L., Shields D.C., Woodside J.V., et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 1999; 17: 298-309.
58. Wang X.L., Cai H., Cranney G., et al. The frequency of a common mutation of the methionine synthase gene in the Australian population and its relation to smoking and coronary artery disease. J Cardiovasc Risk 1998; 5: 289-295.
59. Garrow T.A. Purification, kinetic properties, and cDNA cloning of mammalian betaine-homocysteine methyltransferase. J Biol Chem 1996; 271: 22831-22838.
60. Vaughn J.D., Bailey L.B., Shelnutt K.P., et al. Methionine synthase reductase 66A→G polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677C→T variant. J Nutr 2004; 134: 2985-2990.
61. Jacques P.F., Bostom A.G., Selhub J., et al. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study. Atherosclerosis 2003; 166: 49-55.
62. Lotta T., Vidgren J., Tilgmann C., et al. Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the termolabile variant of the enzyme. Biochemistry 1995; 34: 4202-4210.
63. Zhu B.T. On the mechanism of homocysteine pathophysiology and pathogenesis: a unifying hypothesis. Histol Histopathol 2002; 17: 1283-1291.
64. Zhu B.T. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002; 3: 321-349.
65. Białecka M., Droździk M., Kłodowska-Duda G., et al. Effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphism on levodopa therapy in patients with sporadic Parkinson disease. Acta Neurol Scand 2004; 110: 260-266.
66. Heil S.G., Lievers K.J., Boers G.H., et al. Betaine-homocysteine methyltransferase (BHMT): genomic sequencing and relevance to hyperhomocysteinemia and vascular disease in humans. Mol Genet Metab 2000; 71: 511-519.
67. Morin I., Platt R., Weisberg I., et al. Common variant in betaine-homocysteine methyltransferase (BHMT) and risk for spina bifida. Am J Med Genet A 2003; 119A: 172-176.
68. Goodman J.E., Lavigne J.A., Wu K. COMT genotype, micronutrients in the folate metabolic pathway and breast cancer risk. Carcinogenesis 2001; 22: 1661-1665.
69. Voutilainen S., Tuomainen T. P., Korhonen M., et al. Functional COMT Val158Met polymorphism, risk of acute coronary events and serum homocysteine: the kuopio ischaemic heart disease risk factor study. PLoS One 2007: 2: e181.
70. Shaw G.M., Lammer E.J., Zhu H., et al. Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 2002; 108: 1-6.
71. Devlin A.M., Clarke R., Birks J., et al. Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. Am J Clin Nutr 2006; 83: 708-13.
72. Hancock D.B., Martin E.R., Stajich J.M., et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol 2007; 64: 576-580.
73. Shea T.B., Lyons-Weiler J., Rogers E. Homocysteine, folate deprivation and Alzheimer's neuropathology. J Alzheimer Dis 2002; 4: 261-267.
74. Ho P.I., Collins S.C., Dhitavat S., et al. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 2001; 78: 249-253.
75. Kruman I.I., Culmsee C., Chan S.L., et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20: 6920-6926.
76. de Lau L.M., Koudstaal P.J., Witteman J.C., et al. Dietary folate, vitamin B12 and vitamin B6 and the risk of Parkinson's Disease. Neurology 2006; 67: 315-318.
77. Chen H., Zhang S.M., Schwarzschild M.A., et al. Folate intake and risk of Parkinson's disease. Am J Epidemiol 2004; 160: 368-375.
78. Irizarry M.C., Gurol M.E., Raju S., et al. Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease. Neurology 2005; 65: 1402-1408.
79. Hassin-Baer S., Cohen O., Vakil E., et al. Plasma homocysteine levels and Parkinson's disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006; 29: 305-311.
80. Lamberti P., Zoccolella S., Armenise E., et al. Hyperhomocysteinemia in L-dopa treated parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005; 12: 365-368.
81. Ozer F., Meral H., Hanoglu L., et al. Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 2006; 28: 853-858.
82. O'Suilleabhain P.E., Bottiglieri T., Dewey R.B. Jr., et al. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004; 19: 1403-1408.78.
83. Miller J.W., Selhub J., Nadeau M.R., et al. Effects of L-dopa on plasma homocysteine in PD patients. Relationship to B-vitamin status. Neurology 2003; 60: 1125-1129.
84. Rogers J.D., Sanchez-Saffon A., Frol A.B., et al. Elevated plasma homocysteine levels in patients treated with levodopa. Arch Neurol 2003; 60: 59-64.
85. Nissinen E., Nissinen H., Larjonmaa H., et al. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 2005; 112: 1213-1221.
86. Valkovic P., Benetin J., Blazicek P., et al. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005; 11: 253-256.
87. Zoccolella S., Lamberti P., Armenise E., et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 2005; 11: 131-133.
88. Haugarvoll K., Aarsland D., Wentzel-Larsen T., et al. The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurol Scand 2005; 112: 386-390.
89. Derejko M., Slawek J., Wieczorek D., et al. The influence of vascular risk factors and white matter hyperintensities on the degree of motor impairment in Parkinson's disease. Neurol Neurochir Pol 2006; 40: 276-283.
90. McCann S.J., LeCouteur D.G., Green A.C., et al. The epidemiology of Parkinson's disease in Australian population. Neuroepidemiology 1998; 17: 310-317.
91. Korten A., Lodder J., Vreeling F., et al. Stroke and idiopathic Parkinson's Disease: does the shortage of dopamine offer protection against stroke. Mov Disord 2001; 16: 119-123.
92. Vermeer S.E., Prinds N.D., den Hejer T., et al. Silent brain infarcts and the risk of dementia and and cognitive decline. N Engl J Med 2003; 348: 1215-1222.
93. Martignoni E., Tassorelli C., Nappi G., et al. Homocysteine and Parkinson's disease: a dangerous liaison? Neurol Sci 2007; 257: 31-7.
94. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischaemic stroke to prevent reccurent stroke, myocardial infarction and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized, controlled trial. JAMA 2004; 291: 565-575.
95. Muller T., Wojtalla D., Hauptman B., et al. Decrease of methionine and S-adenozylomethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 2001; 308: 54-56.
96. Ellinson M., Thomas J., Patterson A. A critical evaluation of the relatioship between serum vitamine B, folate and total homocysteine with cognitive impairment in the elderly. J Hum Nutr Diet 2004; 17: 371-383.